Adams G E, Bremner J C, Counsell C J, Stratford I J, Thomas C, Wood P J
MRC Radiobiology Unit, Didcot, Oxon, U.K.
Int J Radiat Oncol Biol Phys. 1992;22(3):467-71. doi: 10.1016/0360-3016(92)90855-c.
The responses of two experimental murine tumors and two human tumor xenografts to the vasodilator hydralazine were compared using two magnetic resonance spectroscopy endpoints. Changes in tumor metabolism were determined using 31P MRS where inorganic phosphate levels relative to total phosphate (Pi/total) were measured, and alteration in tumor blood volume was examined using 19F MRS with perfluorooctylbromide (PFOB) as tracer. The integrated 19F signal from PFOB is dose dependent and stable for at least 2 hr after injection. The murine tumors SCCVII/Ha and KHT both showed changes in tumor metabolism after hydralazine, as an increase in Pi/total. However, hydralazine reduced vascular volume in the KHT tumor, demonstrated by reduced 19F signal from PFOB, but no such reduction was seen in the SCCVII/Ha tumor. In contrast, hydralazine had no effect on phosphorus metabolism in the HT29 and HX118 human tumor xenografts, but reduced vascular volume in both tumors. These results demonstrate that the effects of vasoactive agents such as hydralazine on tumor phosphorus metabolism are only partially consistent with changes in vascular volume, measured by the 19F MRS technique.
使用两个磁共振波谱终点比较了两种实验性小鼠肿瘤和两个人类肿瘤异种移植对血管扩张剂肼屈嗪的反应。使用31P MRS测定肿瘤代谢变化，测量相对于总磷酸盐的无机磷酸盐水平（Pi/总），并使用全氟辛基溴（PFOB）作为示踪剂的19F MRS检查肿瘤血容量的变化。PFOB的积分19F信号是剂量依赖性的，注射后至少2小时稳定。小鼠肿瘤SCCVII/Ha和KHT在使用肼屈嗪后均显示肿瘤代谢变化，表现为Pi/总增加。然而，肼屈嗪降低了KHT肿瘤中的血管容量，这通过PFOB的19F信号降低得以证明，但在SCCVII/Ha肿瘤中未观察到这种降低。相比之下，肼屈嗪对HT29和HX118人肿瘤异种移植中的磷代谢没有影响，但降低了两种肿瘤中的血管容量。这些结果表明，诸如肼屈嗪等血管活性药物对肿瘤磷代谢的影响仅部分与通过19F MRS技术测量的血管容量变化一致。
